~~<i id='4A6D7F8A8B'><strike id='4A6D7F8A8B'><tt id='4A6D7F8A8B'><pre id='4A6D7F8A8B'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：hotspot 2025-09-28 10:45:32 Page View：46

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Listen: Who gets the credit for GLP
Next article： ChatGPT in medicine: STAT answers readers' burning questions

explore

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Health tech startups drop sharply from 2021 highs

AdobeInlessthantwoyears,digitalhealth’shigh-flyingclassofpublicdebutshavelandedwitharesoundingthud.A

Medicare proposal to cover medical devices draws a mixed reaction

AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

How one patient went off dialysis — and others can too

Melissa“Liddy”LawsonphotographedinSanFrancisco,whereshewashospitalizedfornearlysixmonths.ConstanzaHe